View this email in your browser
BIA Separations is now part of Sartorius Stedim Biotech. Learn more >
New approach - High yield mRNA production process from E.coli to highly pure mRNA 
Last month, on the Nucleic Acids conference, Aleš Štrancar, Managing Director of BIA Separations, a Sartorius company, presented our new, groundbreaking mRNA production process. If you’ve missed his talk, click here and discover the basics of our efficient and economic approach.
For more information and knowledge about our flexible toolbox for purification of mRNA, visit this page and listen to Rok Sekirnik’s workshop, presented at the same event.
New publication - Multiple-Monitor HPLC Assays for Rapid Process Development, In-Process Monitoring, and Validation of AAV Production and Purification
HPLC is established as a fast convenient analytical technology for characterizing the content of empty and full capsids in purified samples containing adeno-associated virus (AAV). The present study combines dual-wavelength UV monitoring with intrinsic fluorescence, extrinsic fluorescence, and light-scattering to extend the utility of HPLC for supporting development of therapeutic AAV-based drugs. Click here for further information.
New publication -  Streamlining Industrial Purification of Adeno-Associated Virus

With its first licensed therapeutic now marketed worldwide, adeno-associated virus (AAV) has become a preferred vector for gene therapy.
However, unlocking its full potential still poses challenges, many of which are associated with purification. The following article identifies those challenges and shares experimental data showing how they can be addressed to advance the evolution of gene therapy with AAV.
New publication - Composition of the immunoglobulin G glycome associates with the severity of COVID-19

A large variation in the severity of disease symptoms is one of the key open questions in COVID-19 pandemics. The fact that only a small subset of people infected with SARS-CoV-2 develops severe disease suggests that there have to be some predisposing factors, but biomarkers that reliably predict disease severity have not been found so far. In this publication the association of inter-individual variation in IgG N-glycome composition with the severity of COVID-19 was evaluated.
WEBINAR: Integrated mRNA Production Process from E. coli to Highly Purified mRNA
Date: March 10, 2021
Time: 10 a.m. EST | 7 a.m. PST | 4:00 p.m. CET
Reserve your spot
In vitro transcription (IVT) is the enzymatic process used for mRNA vaccine production. It differs from biological fermentation processes as it requires linearized plasmid DNA. This linear isoform is produced with restriction enzymes from open circular and supercoiled pDNA. However, employing a traditional pDNA manufacturing process, which removes linear and open-circular isoforms, reduces the production yield. This webinar explores the advantages of treating pDNA and mRNA as a single production process. By doing so, purification steps can be optimized, yields improved, and overall production costs reduced.
Copyright © 2021 BIA Separations, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp